Live Breaking News & Updates on European society of retina specialists

Stay updated with breaking news from European society of retina specialists. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Nanoscope Therapeutics Announces Presentation of Positive Results from Optogenetic Gene Therapy for Retinal Degenerative Diseases at the EURETINA 2021 Virtual Conference

Nanoscope Therapeutics Announces Presentation of Positive Results from Optogenetic Gene Therapy for Retinal Degenerative Diseases at the EURETINA 2021 Virtual Conference
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Bedford , Texas , United-states , Michael-carlson , Dan-eramian , Santosh-mahapatra , European-society-of-retina-specialists , Drug-administration , Opus-biotech-communications , Nanoscope-therapeutics-inc , Conference-september , European-society

Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program | Antibodies

Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program ....

Australia , Japan , United-states , Canada , United-kingdom , Switzerland , America , Canadian , Lookeren-campagne , Beovu-basel , John-tsai , Twitter

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program

NOVARTIS AG CHF0.50(REGD)
Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program
Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program
Beovu (brolucizumab) met MERLIN’s primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus aflibercept when given every four weeks following the loading phase
1
In this study evaluating every four week dosing, Beovu was associated with higher rates of IOI including retinal vasculitis and retinal vascular occlusion versus aflibercept ....

Australia , Japan , United-states , Canada , United-kingdom , Switzerland , America , Canadian , Isabella-zinck , Rachel-fink , Lookeren-campagne , Thomas-hungerbuehler

Novartis Pharma AG: Novartis reports one year results of Phase III MERLIN study evaluating Beovu every four week dosing and provides update on Beovu clinical program

Beovu (brolucizumab) met MERLIN's primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus aflibercept ....

Australia , Japan , United-states , Canada , United-kingdom , Switzerland , America , Canadian , Isabella-zinck , Rachel-fink , Lookeren-campagne , Thomas-hungerbuehler

Novartis reports one year results of Phase III MERLIN study evaluating BEOVU® every four week dosing and provides update on BEOVU clinical program

/PRNewswire/ Today, Novartis reported the first interpretable year one results of the Phase III MERLIN study, a two-year study initiated in H2 2018,. ....

Australia , Japan , United-states , Canada , United-kingdom , Switzerland , America , Canadian , Lookeren-campagne , Beovu-basel , John-tsai , Twitter